QUARTERLY IN DEPTH INVESTMENT ANALYSIS – BIOTECH UPDATE (NYSE: CYBN)
I have been watching $CYBN for quite some time and believe that I am starting to get a very good feel for the name, hence why I think the timing is right for another thesis update. Not only do I think that the chart is starting to look really good technically, there is a lot that
QUARTERLY IN DEPTH INVESTMENT ANALYSIS UPDATE – CYBIN INC (NYSE: CYBN)
Disseminated on behalf of CYBN Inc (CYBN)QUARTERLY IN DEPTH ANALYSIS UPDATECYBIN INCThis communication is not an offer to buy or sell securities nor is it to be construed as personal investment advice. Nothing contained in this communication should be relied upon as a promise or representation as to future performance. As I mentioned yesterday during the Live
QUARTERLY IN DEPTH INVESTMENT ANALYSIS – CYBIN INC (NYSE: CYBN)
This quarter I am going to be covering a Biotech name that I feel, after extensive due diligence and interviewing members from the executive team (including the CEO, Doug Drysdale) is in a good position to gain additional market share and growth in the short and medium term.